





ITT/ :

( 37.5° ), >15 / , >10 500/ <sup>3</sup> ,

( ) - 72

14 . ( ) 8 ( ), 80%

( 5- 24- ) , " " .

48 ( ) , /

*gonorrhoeae* . *trachomatis*, N.

24 , - *Diphtheroids*, *Corynebacterium Lactobacillus*.

QT ( ) 5- 24- ) .

QT, - ; >70% ( / / )

( , / <38.0° <37.5° ) <10 500/ <sup>3</sup> .

-6 - (>30 ) McCormack<sup>7</sup>:

7 , 30

0 = 237  
1 = >-10%.

2 = 760  
(97.5%) 749, 741  
3 = intent-to-treat (ITT;  
")  
")  
*per-protocol analyses* ( ;  
")  
36. 564 (74.2%), 109  
(28%)  
76 (21%)

28- 42- ( )  
( 5- 24- ( <0.05) ( 1).  
( 28- 42- 112/564  
(19.9%)  
: ( 5  
/ )  
" ( )  
: 90.2% (248/275)  
90.7% (262/289)

ITT/  
(95% :-5.7%, 4.0%) ( 1).

MedDRA. ( " )  
88.1% (236/268)  
90.4% (254/281)  
(95% :-7.8%, 2.6%)  
Haenszel Mantel-  
95%- ( 1).  
( ) ( " )  
75.7% (286/378)  
82.6% (300/363)

10.8%, 0.4%). (95% ITT (284/378) 75.1%  
 (294/363) 81.0%  
 (95% fIH: -9.96%; 1.6%).

1

	(N = 275)	(N =289)	
n (%)			
	144 (52.4)	160(55.4)	0.764
	99 (36.0)	93 (32.2)	
	32(11.6)	36(12.5)	
± SD	29.7±8.1	30.6 ± 8.5	0.231
± SD	64.0±13.10.2	64.0±13.1	0.242
± SD	162.9 ±6.7	162.2 ± 7.2	0.121
(%)			
:	171 (62.2)	205 (70.9)	0.016
:	160 (58.2)	182(63.0)	0.566
:	66 (24.0)	82 (28.4)	0.794
:	240 (87.3)	257 (88.9)	0.434
:	18 (6.5)	18 (6.2)	0.717
	249 (90.5)	254 (87.9)	0.169
<sup>b</sup>	26 (9.5)	35(12.1)	
<3	45(16.4)	69 (23.9)	0.816
> 3	230 (83.6)	220(76.1)	
<7	123 (44.7)	147 (50.9)	
> 7	152 (55.3)	142(49.1)	
12			
0	193 (70.2)	202 (69.9)	0.870
1	45 (16.4)	54(18.7)	
	37(13.5)	33(11.4)	
( ± SD	16.5 ±6.5	16.7 ±6.7	0.400
± SD			
	7.7 ±4.8	8.0 ±5.1	0.296
	8.7 ± 2.4	8.7 ±2.4	00.873
10.5(GIGA/L)	37(13.5)	46 (15.9)	0.685
(GIGA/L, ± SD	4.6 ± 2.5	4.8 ± 2.9	0.378
- > 0.5 /	93 (33.8)	94 (32.5)	0.956
> 15 /	182(66.2)	184(63.7)	0.573

<sup>a</sup> ( ) ANOVA ( ).

<sup>b</sup> 62/68

(49/56)

82.1% (46/56;

-  
- (95% : -8.3%, 18.8%) ( 2).  
87.5%

2

( / ) ( )

, n/Na (%)	(N=56)	(N = 56)
	70/77 (90.9)	70/81 (86.4)
	87/12 (66.7)	5/8 (62.5)
	8/12 (66.7)	5/8 (62.5)
<i>Streptococcus agalactiae</i>	3/4 (75.0)	0/3 (0)
<i>Gardnerella vaginalis</i>	0/3 (0)	1/1 (100)
<i>Staphylococcus aureus</i>	1/1 (100)	1/1 (100)
<i>Streptococcus</i>	1/1 (100)	0
<i>Streptococcus anginosus</i>	1/1 (100)	2/2 (100)
<i>Streptococcus acidominimus</i>	0	1/1 (100)
<i>Streptococcus mitis</i>	1/1 (100)	0
<i>Enterococcus faecalis</i>	1/1 (100)	0
	19/19(100)	22/27(81.5)
	21/21 (100)	23/28(82.1)
<i>Neisseria gonorrhoeae</i>	13/13(100)	18/22(81.8)
<i>Escherichia coli</i>	5/5(100)	4/4 (100)
<i>Citrobacter koseri</i>	1/1 (100)	0
<i>Haemophilus influenzae</i>	1/1 (100)	0
<i>Klebsiella pneumoniae</i>	0	0/1 (0)
<i>Proteus mirabilis</i>	0	1/1 (100)
<i>Proteus vulgaris</i>	1/1 (100)	0
	3/3(100)	6/6 (100)
	4/4(100)	7/7 (100)
<i>Actinomyces neuii</i>	0	1/1 (100)
<i>Bacteroides fragilis</i>	0	1/1 (100)
<i>Clostridium sordelli</i>	0	1/1 (100)
<i>Clostridium spp.</i>	1/1 (100)	0
<i>Clostridium sporogenes</i>	1/1 (100)	0
<i>Peptostreptococcus anaerobius</i>	1/1 (100)	1/1 (100)
<i>Peptostreptococcus prevotii</i>	0	1/1 (100)
<i>Porphyromonas asaccharolytica</i>	1/1 (100)	1/1 (100)
<i>Prevotella melaninogenica</i>	0	1/1 (100)
« »	35/37b (94.6)	31/34(91.2)
	37/40 (92.5)	35/38(92.1)
<i>Chlamydia trachomatis</i>	23/26b (88.5)	18/21 (85.7)
hominis	11/11 (100)	16/16 (100)
genitalium	3/3 (100)	1/1 (100)

a

b

1

(

/


)

( -

"


"

81.1% (43/53) 79.3% (112 [30.9%])  
 (42/53) ( = 0.01) ( 3).  
 95% CI: -13.8%, 17.1%) ( -  
 2). 112 158 -  
 gonorrhoeae ( = 35) ( 2). N. (14.3% 19.6%,  
 = 0.055) ( 3). (5.6%),  
 88.5% (23/26)  
 100% (13/13), ( 2). 24 (6.3%),  
 - 18 (5.0%) ( = 0.41).  
 85.7% (18/21) 81.8%  
 (18/22), ( 2). 11 (2.9%) 8  
 (2.2%)  
 741  
 (179 [47.4%]),  
 (200  
 [55.1%]), ( = 0.035).  
 3  
 (85 [22.5%]),



1

( 28- 42- ( 5- 24- ) (N = 564).



2

(N=112). ( 28- 42- ( 5- 24- ) )

3

1 % ( / ).

	, n%	(N = 378)	(N=363)
1		85 (22.5)	112(30.9)
-		54 (14.3)	71 (19.6)
		31 (8.2)	51 (14.0)
		9 (2.4)	6(1.7)
		9(2.4)	6(1.7)
		4(1.1)	5(1.4)
		4(1.1)	4(1.1)
		4(1.1)	2(0.6)
		1 (0.3)	4(1.1)
		4(1.1)	-
		13(3.4)	7(1.9)
		7(1.9)	4(1.1)
		11 (2.9)	17(4.7)
		5(1.3)	9(2.5)
		4(1.1)	7(1.9)
		18 (4.8)	32 (8.8)
		6(1.6)	17 (4.7)
		9(2.4)	9 (2.5)
		3(0.8)	14(3.9)
		2 (0.5)	5(1.4)
		3 (0.8)	6(1.7)
		2(0.5)	4(1.1)
		6(1.6)	8 (2.2)

( )



( , 2.6% , 8.8%, =  
 0.0003).  
 Pharmaceuticals Corporation. - Bayer HealthCare  
 16- ,  
 13 2005 , ISSTD, , , 10-

400  
 14

400

500  
 14

1. Sweet RL. *Infect Dis Clin North Am* 1987; 1: 199-215.
2. Centers for Disease Control. *Sexually Transmitted Diseases Treatment Guidelines 2002*. MMWR 2002; 51(RR06): 1-80.
3. Woodcock JM, Andrews JM, Boswell FJ, et al. *Antimicrob Agents Chemother* 1997; 41:101-106.
4. Donati M, Rodriguez Fermepin M, Olmo A, et al. *J Antimicrob Chemother* 1997; 43: 825-827.
5. Aldridge KE, Ashcraft DS. *Antimicrob Agents Chemother* 1997; 41: 709-711.
6. Heystek MJ, Tellarini M, Schmitz H, Krasemann for the PID study group. Presented at the 21st International Congress of Chemotherapy, Birmingham, UK, 1999. *J Antimicrob Chemother* 1999; 44 (suppl A): Abstract P-466.
7. McCormack WM, Nowroozi K, Alpert S, et al. *Sex Transm Dis* 1977; 4: 125-131.
8. Moyle G. *Int J STD AIDS* 2003; 14 (Suppl 1): 34-36.